A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis
Status:
Not yet recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
Q05105 tablet is a Janus kinase 2 (JAK2) inhibitor, which can be used to treat JAK2 target
related diseases, such as moderate or high-risk multiple myelofibrosis